Novo Nordisk A/S (TSX:NOVO)

Market Cap	313.06B -24.1%
Revenue (ttm)	70.59B +8.1%
Net Income	26.26B +16.6%
EPS	5.90 +16.8%
Shares Out	n/a
PE Ratio	11.92
Forward PE	16.55
Dividend	0.52 (2.40%)
Ex-Dividend Date	Mar 30, 2026

Volume	3,280
Open	21.80
Previous Close	21.98
Day's Range	21.50 - 21.80
52-Week Range	14.88 - 27.58
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 67,900
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: NOVO

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 18, 2026

Data Sources Report a data error